Lenalidomid Sandoz

Lenalidomide, the active ingredient in Lenalidomid Sandoz, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution networks across Europe, Asia and the Americas.

Lenalidomid Sandoz is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma‑cell and lymphoid proliferation through immunomodulation. - Multiple myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents. - Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission. - Mantle cell lymphoma: provides disease control as part of combination therapy in relapsed or refractory cases.

Lenalidomid Sandoz may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Thrombocytopenia: low platelet levels, may cause bleeding. - Anemia: decreased red blood cell count, leading to fatigue. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools, may require hydration. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils with fever. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Embryo‑fetal toxicity: potential harm to developing fetus. - Stevens‑Johnson syndrome: severe skin and mucosal reaction.

Before prescribing Lenalidomid Sandoz, clinicians should consider several safety and handling precautions. - Baseline blood counts: obtain CBC to assess neutrophils, platelets and hemoglobin. - Thrombo‑prophylaxis: evaluate need for anticoagulation in patients at risk of clotting. - Renal function: adjust monitoring in patients with impaired kidney function. - Hepatic function: monitor liver enzymes during therapy. - Pregnancy risk: avoid use in pregnancy; ensure effective contraception for women of childbearing potential. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomid Sandoz can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunosuppressive effects. - Vaccines: live attenuated vaccines should be avoided due to altered immune response. - NSAIDs: may increase risk of renal impairment when combined with lenalidomide‑related dehydration.